EDIT
Editas Medicine, Inc.
There isn't enough reported data to score EDIT yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
EDIT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
EDIT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
EDIT PE Valuation
EDIT has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
EDIT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect EDIT's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
EDIT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.62 | +$1.76 |
| Q2 2026 | -$0.75 | +$2.10 |
| Q1 2026 | -$1.23 | +$1.81 |
| Q4 2025 | -$1.89 | +$0.99 |
| Q3 2025 | -$2.38 | +$0.15 |
| Q2 2025 | -$2.85 | -$0.52 |
| Q1 2025 | -$3.04 | -$0.97 |
| Q4 2024 | -$2.88 | -$0.86 |
EDIT is still losing money, but far less than before: $0.62 per share over the past year, against $3.24 at its worst in late 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over EDIT on earnings quality, reporting a profit while its opponent remains loss making.
EDIT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.4M | +37% |
| Q2 2026 | $11.9M | +232% |
| Q1 2026 | $2.8M | -39% |
| Q4 2025 | $24.7M | -19% |
| Q3 2025 | $7.5M | +12266% |
| Q2 2025 | $3.6M | +597% |
| Q1 2025 | $4.7M | +310% |
| Q4 2024 | $30.6M | -49% |
EDIT's revenue is recovering but still below its 2020 peak: $10M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -234% | +91 points |
| Q2 2026 | -156% | +1285 points |
| Q1 2026 | -883% | +752 points |
| Q4 2025 | -31% | +121 points |
| Q3 2025 | -325% | +107324 points |
| Q2 2025 | -1441% | +12576 points |
| Q1 2025 | -1635% | +4267 points |
| Q4 2024 | -152% | -112 points |
EDIT's operating margin was −234% last quarter, up 91 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over EDIT on profitability, with a higher operating margin.
EDIT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$21.2M | +$10.1M |
| Q2 2026 | -$29.7M | +$20.5M |
| Q1 2026 | -$23.2M | +$24.8M |
| Q4 2025 | -$36.4M | +$14.9M |
| Q3 2025 | -$31.3M | +$24.2M |
| Q2 2025 | -$50.2M | +$10.3M |
| Q1 2025 | -$47.9M | +$3.8M |
| Q4 2024 | -$51.3M | -$27.8M |
EDIT has burned cash in almost every quarter: −$110M over the past year, against −$181M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over EDIT on cash generation, producing positive trailing cash flow while its opponent burns cash.
EDIT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +29% | +34.3M shares |
| 1 year | +71% | +63.5M shares |
| 3 years | +88% | +72M shares |
| 5 years | +125% | +85.4M shares |
| Available history | +207% | +104M shares |
EDIT has 154M diluted shares, up 71% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over EDIT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
EDIT Net Leverage
EDIT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
EDIT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.6 | Neutral |
| Stochastic | 20.1 | Neutral |
EDIT's weekly RSI is 42 (neutral) and its Stochastic is 20 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
EDIT PE vs Healthcare Sector
EDIT has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
EDIT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.53 | 15% below |
| 20 week MA | $2.79 | 23% below |
| 50 week MA | $2.60 | 18% below |
| 100 week MA | $2.37 | 9.7% below |
| 200 week MA | $4.70 | 54% below |
EDIT is in a downtrend: it's below all five of its weekly moving averages, and 54% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over EDIT on trend strength, trading above more of its moving averages.
EDIT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.5 | $83.5 | +174% |
| 2021 | $83.5 | $29.9 | -64% |
| 2022 | $29.9 | $8.84 | -70% |
| 2023 | $8.84 | $10.1 | +15% |
| 2024 | $10.1 | $1.21 | -88% |
| 2025 | $1.21 | $2.17 | +79% |
| 2026 YTD | $2.17 | $2.14 | -1.4% |
EDIT's yearly returns have swung widely, from +174% in 2020 to −88% in 2024. It's down 1.4% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over EDIT on returns for 2026, with the stronger performance.